| __timestamp | MorphoSys AG | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 77000 | 205018000 |
| Thursday, January 1, 2015 | 77000 | 392709000 |
| Friday, January 1, 2016 | 97000 | 299694000 |
| Sunday, January 1, 2017 | 33000 | 397061000 |
| Monday, January 1, 2018 | 1796629 | 434100000 |
| Tuesday, January 1, 2019 | 12085198 | 782200000 |
| Wednesday, January 1, 2020 | 9174146 | 1119900000 |
| Friday, January 1, 2021 | 32200000 | 2437500000 |
| Saturday, January 1, 2022 | 48620000 | 1560400000 |
| Sunday, January 1, 2023 | 58355000 | 1815800000 |
| Monday, January 1, 2024 | 1970500000 |
Unleashing the power of data
In the competitive world of biotechnology, cost efficiency is a critical factor for success. Regeneron Pharmaceuticals, Inc. and MorphoSys AG, two giants in the industry, have shown contrasting trends in their cost of revenue from 2014 to 2023.
Regeneron, a leader in the field, has consistently maintained a higher cost of revenue, peaking at approximately $1.8 billion in 2023. This represents a staggering 785% increase from 2014. In contrast, MorphoSys AG, while starting with a modest cost of revenue, has seen a dramatic rise, reaching around $58 million in 2023, marking an exponential growth of over 75,000% since 2014.
These figures highlight the differing strategies and market positions of these companies. While Regeneron’s substantial costs reflect its expansive operations, MorphoSys’s rapid growth indicates its aggressive expansion in recent years.
AbbVie Inc. vs MorphoSys AG: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Bristol-Myers Squibb Company and MorphoSys AG
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs Intra-Cellular Therapies, Inc.
Cost of Revenue Comparison: Regeneron Pharmaceuticals, Inc. vs Incyte Corporation
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Lantheus Holdings, Inc.
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Perrigo Company plc's Expenses
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs ACADIA Pharmaceuticals Inc.
Regeneron Pharmaceuticals, Inc. vs Xencor, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Takeda Pharmaceutical Company Limited and MorphoSys AG
Cost of Revenue Trends: Corcept Therapeutics Incorporated vs MorphoSys AG
Cost of Revenue Comparison: Cytokinetics, Incorporated vs MorphoSys AG
Analyzing Cost of Revenue: MorphoSys AG and Wave Life Sciences Ltd.